为肝细胞癌武装 GPC3 CAR-T 细胞：多少才足够，下一步是什么？
Armouring GPC3 CAR T cells for hepatocellular carcinoma: how much is enough and what comes next?
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
肝细胞癌与免疫治疗：超越免疫检查点抑制剂
英文原题：Hepatocellular carcinoma and immunotherapy: Beyond immune checkpoint inhibitors.
查看英文原题
Hepatocellular carcinoma and immunotherapy: Beyond immune checkpoint inhibitors.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
肝细胞癌（HCC）是肝脏最常见且最致命的恶性肿瘤之一。鉴于HCC癌变过程中具有丰富的免疫背景，研究重点一直集中在进一步了解免疫系统在肿瘤抑制和促进中的作用。免疫治疗在HCC中的应用已取得令人鼓舞的结果，转化为患者更长的生存期和更好的生活质量。开发针对HCC的新型治疗方案，如疫苗治疗和过继性细胞治疗，结合对预测免疫治疗反应的生物标志物的更深入理解，将带来更好的治疗结果。
展开英文摘要原文
Hepatocellular carcinoma (HCC) is one of the deadliest and most common malignancies of the liver. Considering the rich immune background of carcinogenesis in HCC, efforts have been focused on further understanding the role of the immune system in tumor suppression and promotion.
The utilization of immunotherapy in HCC has led to encouraging results that has translated to longer survival and better quality of life among patients. The development of novel HCC-tailored regimens such as vaccine therapy and adoptive cellular therapy coupled with a deeper understanding of biomarkers predictive of the response to immunotherapy will lead to better treatment outcomes.
论文信息
- 作者
- Abushukair HM、Saeed A
- 第一作者单位
- Faculty of Medicine, Jordan University of Science and Technology, Irbid 22110, Jordan.Jordan
- 通讯作者单位
- Division of Medical Oncology, Department of Medicine, The University of Kansas Cancer Center, Kansas City, KS 66205, United States. asaeed@kumc.edu.United States
- 期刊
- World journal of gastrointestinal oncology2022 Jun 15
- 原文标识
- PubMed 35949209 · DOI 10.4251/wjgo.v14.i6.1210
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →